Lipidomics studies on macrophages - bone marrow-derived macrophages treated with 25-hydroxy-cholesterol +/- lipid-depleted media containing compactin
Introduction | Browse | DownloadMouse-over the above links for more information
Treatment details
| LM ID | Analyte | Treatment | Time(hrs) | Sample ID | Value | Units |
|---|---|---|---|---|---|---|
| LMFA01030089 | cis-erucic acid | Lipid-depleted/compactin | 0.0 | BCD100322A002 | 4.4 | pmol/sample |
| LMFA01030089 | cis-erucic acid | Lipid-depleted/compactin | 0.5 | BCD100322A005 | 5.61 | pmol/sample |
| LMFA01030089 | cis-erucic acid | Lipid-depleted/compactin | 1.0 | BCD100322A009 | 7.21 | pmol/sample |
| LMFA01030089 | cis-erucic acid | Lipid-depleted/compactin | 2.0 | BCD100322A013 | 4.8 | pmol/sample |
| LMFA01030089 | cis-erucic acid | Lipid-depleted/compactin | 4.0 | BCD100322A017 | 3.05 | pmol/sample |
| LMFA01030089 | cis-erucic acid | Lipid-depleted/compactin | 8.0 | BCD100322A021 | 2.01 | pmol/sample |
| LMFA01030089 | cis-erucic acid | Lipid-depleted/compactin | 12.0 | BCD100322A025 | 1.08 | pmol/sample |
| LMFA01030089 | cis-erucic acid | Lipid-depleted/compactin | 24.0 | BCD100322A029 | - | pmol/sample |
| LMFA01030089 | cis-erucic acid | C | 0.0 | BCD100322A001 | 1.64 | pmol/sample |
| LMFA01030089 | cis-erucic acid | C | 0.5 | BCD100322A003 | 2.4 | pmol/sample |
| LMFA01030089 | cis-erucic acid | C | 1.0 | BCD100322A007 | 3.34 | pmol/sample |
| LMFA01030089 | cis-erucic acid | C | 2.0 | BCD100322A011 | 0.86 | pmol/sample |
| LMFA01030089 | cis-erucic acid | C | 4.0 | BCD100322A015 | 4.44 | pmol/sample |
| LMFA01030089 | cis-erucic acid | C | 8.0 | BCD100322A019 | 0.91 | pmol/sample |
| LMFA01030089 | cis-erucic acid | C | 12.0 | BCD100322A023 | - | pmol/sample |
| LMFA01030089 | cis-erucic acid | C | 24.0 | BCD100322A027 | 4.49 | pmol/sample |
| LMFA01030089 | cis-erucic acid | 25OH-Chol + Lipid-depleted/compactin | 0.5 | BCD100322A006 | 5.53 | pmol/sample |
| LMFA01030089 | cis-erucic acid | 25OH-Chol + Lipid-depleted/compactin | 1.0 | BCD100322A010 | 4.54 | pmol/sample |
| LMFA01030089 | cis-erucic acid | 25OH-Chol + Lipid-depleted/compactin | 2.0 | BCD100322A014 | 5.62 | pmol/sample |
| LMFA01030089 | cis-erucic acid | 25OH-Chol + Lipid-depleted/compactin | 4.0 | BCD100322A018 | 4.3 | pmol/sample |
| LMFA01030089 | cis-erucic acid | 25OH-Chol + Lipid-depleted/compactin | 8.0 | BCD100322A022 | 2.29 | pmol/sample |
| LMFA01030089 | cis-erucic acid | 25OH-Chol + Lipid-depleted/compactin | 12.0 | BCD100322A026 | 5.93 | pmol/sample |
| LMFA01030089 | cis-erucic acid | 25OH-Chol + Lipid-depleted/compactin | 24.0 | BCD100322A030 | 8.13 | pmol/sample |
| LMFA01030089 | cis-erucic acid | 25OH-Chol | 0.5 | BCD100322A004 | 2.81 | pmol/sample |
| LMFA01030089 | cis-erucic acid | 25OH-Chol | 1.0 | BCD100322A008 | 3.94 | pmol/sample |
| LMFA01030089 | cis-erucic acid | 25OH-Chol | 2.0 | BCD100322A012 | 0.72 | pmol/sample |
| LMFA01030089 | cis-erucic acid | 25OH-Chol | 4.0 | BCD100322A016 | 1.86 | pmol/sample |
| LMFA01030089 | cis-erucic acid | 25OH-Chol | 8.0 | BCD100322A020 | 1.63 | pmol/sample |
| LMFA01030089 | cis-erucic acid | 25OH-Chol | 12.0 | BCD100322A024 | 2.34 | pmol/sample |
| LMFA01030089 | cis-erucic acid | 25OH-Chol | 24.0 | BCD100322A028 | - | pmol/sample |